RhumbLine Advisers’s Biodexa Pharmaceuticals BDRX Stock Holding History

RhumbLine Advisers’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Hold	0	–	-$8	–	4058
2026 Q2	–	Hold	0	–	–	–	4124
2026 Q1	–	Sell	-1	Closed	-$56	–	4082
2025 Q4	$54	Buy	+1	New	+$228	﹤0.01%	4101
2025 Q3	–	Hold	0	–	–	–	4100
2025 Q2	–	Sell	-1	Closed	-$510	–	4113
2025 Q1	$414	Buy	+1	New	+$1.4K	﹤0.01%	4066
2024 Q4	–	Sell	-1	Closed	-$2.09K	–	4094
2024 Q3	$1.7K	Buy	+1	New	+$6.13K	﹤0.01%	4067
2024 Q2	–	Hold	0	–	–	–	4168
2024 Q1	–	Hold	0	–	–	–	4162
2023 Q4	–	Hold	0	–	–	–	4130
2023 Q3	–	Hold	0	–	–	–	4174
2023 Q2	–	Hold	0	–	–	–	4362

Other funds holding BDRX

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

RhumbLine Advisers's BDRX Position: Q3 2026 in Review

RhumbLine Advisers held its Biodexa Pharmaceuticals (BDRX) position steady in Q3 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4058.

RhumbLine Advisers first reported a position in BDRX in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.7K in Q3 2024. 4 funds tracked by Wall St. Rank hold BDRX as of Q3 2026.

RhumbLine Advisers held 0 shares of Biodexa Pharmaceuticals worth $0 as of Q3 2026.
RhumbLine Advisers left its Biodexa Pharmaceuticals share count unchanged in Q3 2026.
Biodexa Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #4058 holding.
RhumbLine Advisers first reported a position in Biodexa Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
RhumbLine Advisers's Biodexa Pharmaceuticals position peaked at $1.7K in Q3 2024.
4 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.